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Abstract
Introduction: Minor salivary gland tumors (MSGTs) are infrequent, representing 10-15% of all salivary neoplasms. 
Despite this low frequency, MSGTs conform a heterogeneous group of neoplasms characterized by a broad range 
of histological types.
Patients and method: We identified cases of MSGT in a retrospective study of the biopsies made in the period 
1997-2007 in the Service of Oral Surgery (Dental Clinic of the University of Barcelona, Spain). The data collected 
comprised patient age and sex, the clinical characteristics and location of the tumor, the duration of the lesion, its 
size, the treatment provided, and the histopathological findings.
Results: Of the 18 cases of MSGT studied, 12 corresponded to women (66.7%) and 6 to men (33.3%). The great 
majority (94.4%) were benign tumors. The preferential location was the posterior third of the hard palate (33.2%), 
followed by the soft palate (16.7%) and the mucosa of the upper lip (16.7%). The histopathological diagnoses of our 
MSGTs comprised 10 pleomorphic adenomas (55.3%), 2 cystadenomas (11.1%), 1 myoepithelioma (5.6%), 1 siala-
denoma papilliferum (5.6%), 1 basal cell adenoma (5.6%), 1 Warthin’s tumor (5.6%), 1 canalicular adenoma (5.6%), 
and 1 low-grade polymorphic adenocarcinoma (5.6%).
Discussion and conclusions: Coinciding with our own results, the literature describes a high recurrence rate for MSGTs 
(5-30%) when surgical removal is incomplete. Six percent of all benign minor salivary gland tumors are considered to 
relapse, versus 65% of all malignant lesions. Periodic clinical controls are required, since the possibility of malignant 
transformation must be taken into account.
Key words: Oral tumors, minor salivary glands, histopathological diagnosis, local recurrence.
Indexed in: 
-Index Medicus / MEDLINE  /  PubMed            
-EMBASE, Excerpta Medica
-SCOPUS
-Indice Médico Español                                                        
-IBECS
              Article Number: 1111111211
              © Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946 
              eMail:  medicina@medicinaoral.com 
Publication Types: Research
Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E582-8.                                                                                                                                                                               Tumors of minor salivary glands                                                                            Med Oral Patol Oral Cir Bucal.  2008 Sep1;13(9):E582-8.                                                                                                                                                                                 Tumors of minor salivary glands
E583
Introduction
Salivary gland neoplasms represent less than 1% of 
all tumors, and 3-5% of all head and neck neoplasms. 
Minor salivary gland tumors (MSGTs) are infrequent, 
accounting for 10-15% of all salivary neoplasms, and are 
fundamentally located in the palate (50%), lips (15%), 
cheek mucosa (12%), tongue (5%) and floor of the mouth 
(5%), among other regions. Despite their relatively low 
frequency, MSGTs represent a heterogeneous group of 
neoplasms, with a broad range of histological types and 
growth patterns. Because of this great diversity and the 
lack of uniform criteria, many classifications have been 
developed, and the establishment of an adequate clinical-
histological correlation proves difficult (1,2).
The first classification of salivary glands tumors, develo-
ped by the World Health Organization (WHO) in 1972, 
was posteriorly revised under the supervision of  Prof. 
Seifert in 1991. The second edition of the histological clas-
sification of salivary gland tumors included new entities 
and suppressed the concept of “monomorphic adenoma”, 
in view of the diversity of the tumors that were grouped 
under this designation - giving rise to 11 independent 
histopathological entities (3). Due to the great morpho-
logical diversity of these tumors and the need to establish 
a precise diagnosis, a consensus meeting was held in Lyon 
(France), giving rise to a new classification of salivary 
gland tumors, published in the year 2005 (4).
The proportion of malignant tumors of the minor sali-
vary glands is very high (50%) – the preferential locations 
being the floor of the mouth (90%), the retromolar tri-
gone (90%), the tongue (85%) and the lower lip (60%). In 
contrast, neoplasms of the upper lip are usually benign 
tumors (75%).
While tumors of the salivary glands can appear at any age, 
the maximum incidence is in the fourth decade of life for 
benign lesions and in the fifth decade for malignant tumors 
though different authors consider the peak incidence to 
correspond to the period between the fifth and seventh 
decades of life. Classically, these lesions have been repor-
ted to be more frequent in women, though the proportion 
varies according to the histological type of tumor.
The etiopathogenesis of MSGTs remains unclear (1). In 
this context, it has not been possible to correlate smoking 
to salivary gland cancer, and exposure to ionizing radiation 
to date has been the only confirmed risk factor for tumors 
of the salivary glands (5,6). 
The most frequent clinical presentation of benign MSGTs 
is in the form of a well delimited, smooth and uniform 
nodular tumor with a normal overlying surface color. 
The lesion is typically asymptomatic and displaceable, 
usually single, and without adherence to either superficial 
or deep layers.
One of the clinical features that allow differentiation bet-
ween benign and malignant MSGTs is the evolutive course, 
since the former tend to be insidious and slow-growing, 
with an average course of  3-6 years, while malignant 
lesions are fast-growing (typically under one year) and 
can ulcerate, become overinfected, and cause external or 
interstitial bleeding  giving rise to superficial telangiecta-
sias. The clinical data most suggestive of malignancy are 
pain, adherence to deep or superficial layers, epidermal 
involvement and/or ulceration, and the presence of neck 
adenopathies. 
MSGTs have a high recurrence rate (5-30%) when surgical 
removal is incomplete, and the possibility of malignant 
transformation must be taken into consideration. Six 
percent of  all benign minor salivary gland tumors are 
considered to relapse, versus 65% of all malignant lesions. 
This capacity to relapse is related to the histopathological 
characteristics of the tumor, and particularly to the initial 
treatment provided. 
The diagnosis of MSGTs is based on the clinical history 
and physical exploration, supported by complementary 
techniques such as magnetic resonance imaging (MRI), 
computed tomography (CT) alone or combined with sia-
lography and fine needle aspiration biopsy (FNAB). The 
combination of some of these techniques is able to offer 
a tentative diagnosis that posteriorly must be confirmed 
by the corresponding intraoperative histopathological 
study.
The present study describes MSGTs according to patient 
age and sex, tumor location, clinical and histopatholo-
gical characteristics, and treatment, based on a series 
of 18 cases. A review of the literature is also made, and 
emphasis is placed on the need for periodic controls, due 
to the important relapse potential and aggressivity of 
these lesions.
Patients and Method
A retrospective study was made of all the biopsies obtained 
between January 1997 and May 2007, in the Service of 
Oral Surgery (Dental Clinic of the University of Barcelo-
na, Spain). During this period of time a total of 1972 biop-
sies were made, of which 18 corresponded to MSGTs (12 
women and 6 men). The diagnosis of MSGT was based on 
clinical and histopathological criteria, and all the patholo-
gy reports were reviewed by the Department of Pathology 
(Bellvitge University Hospital, Barcelona, Spain) based 
on the most recent histological classification of salivary 
gland tumors, published by the WHO in 2005.
All cases identified as MSGTs were treated by residents of 
the Master of Oral Surgery and Implantology (University 
of Barcelona Dental School, Spain), with the exception 
of a single case that was directly referred to Bellvitge Uni-
versity Hospital as a result of histological confirmation of 
malignancy. This was the only case in our series operated 
upon by maxillofacial surgeons – treatment consisting of 
a partial maxillectomy with postoperative radiotherapy, 
followed by second step reconstruction of the upper maxi-
llary defect using a temporal muscle flap.
E584
Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E582-8.                                                                                                                                                                               Tumors of minor salivary glands                                                                            Med Oral Patol Oral Cir Bucal.  2008 Sep1;13(9):E582-8.                                                                                                                                                                                 Tumors of minor salivary glands
From each clinical history we recorded the age and sex 
of the patient, the clinical characteristics and location of 
the tumor, the time elapsed to histopathological diagnosis, 
the size of the tumor, and the definitive histopathological 
diagnosis. We also evaluated the results of the comple-
mentary diagnostic tests, and the possible appearance of 
local relapses over a mean follow-up period of 1.8 years. 
The treatment provided in each case, the biopsy techni-
que used, and the definitive histopathological result were 
documented. In addition, the incidence of MSGTs in our 
Service of Oral Surgery was determined.
Based on these data, a descriptive statistical analysis was 
made using the Statistical Package for the Social Sciences, 
version 12.0 (SPSS v.12.0; SPSS, Chicago, IL, USA).
Results
The proportion of MSGTs in our Service of Oral Surgery 
in relation to the 1972 biopsies performed in the period 
between January 1997 and May 2007 was 0.9%. Eighteen 
MSGTs were identified - pleomorphic adenoma (PA) be-
ing the most frequent histological type (10 cases; 55.3%) 
followed by cystadenoma (2 cases; 11.1%). Other histo-
pathological presentations in our series of MSGTs were 
myoepithelioma (1 case; 5.6%), sialadenoma papilliferum 
(1 case; 5.6%), basal cell adenoma (1 case; 5.6%), Warthin’s 
tumor (1 case; 5.6%), canalicular adenoma (1 case; 5.6%) 
and low-grade polymorphic adenocarcinoma (LGPA)(1 
case; 5.6%). The histopathological diagnoses established 
in our series are reported in Table 1.
The percentage of benign tumors was 94.4% (17 cases), 
and the only malignancy corresponded to LGPA. The be-
nign tumors showed a marked female predilection (58.8%). 
Of the 18 cases of MSGT studied, 12 were recorded in 
women (66.7%) and 6 in men (33.3%), yielding a male/
female proportion of 1:2 (Table 1). The mean patient age 
was 51.8 years (range 22-86 years; standard deviation 
(SD) 18.9). 
The preferential location of MSGTs was the posterior 
                
Case
Age 
(years)
Sex
Histological 
diagnosis
Frequency Location
Course 
(months)
1 38 F
Pleomorphic 
adenoma
55.3 %
Cheek mucosa 12
2 37 M Hard palate 60
3 82 M Hard palate 24
4 36 M Soft palate 72
5 45 F Soft palate 6
6 50 F Retrotuberosity zone 4
7 28 F Hard palate 1
8 51 F Upper lip mucosa 120
9 38 F Cheek mucosa 132
10 54 F Soft palate 240
11 22 F Basal cell adenoma 5.6 % Retromolar trigone 2
12 46 F
Sialadenoma 
papilliferum
5.6 % Hard palate 156
13 50 F
Low-grade 
polymorphic 
adenocarcinoma
5.6 % Hard palate 8
14 61 F Myoepithelioma 5.6 % Upper lip mucosa 24
15 78 M
Cystadenoma 11.1 %
Lower lip mucosa - cheek mucosa 3
16 86 M Retromolar trigone 18
17 73 F Warthin’s tumor 5.6 % Hard palate 96
18 57 M
Canalicular 
adenoma
5.6 % Upper lip mucosa 4
Mean
51.8
F/M
2/1
Hard palate: 33.2%
Lower lip mucosa: 5.6%
Soft palate: 16.7%
Cheek mucosa: 11.1%
Upper lip mucosa: 16.7%
Tuberosity: 5.6%
Retromolar trigone: 11.1%
Mean
55
Table 1. Distribution of minor salivary gland tumors according to patient age and sex, histological diagnosis, frequency, location, 
and duration of the lesions.
F: female, M: male
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Fig. 3. Clinical view of surgical resection – biopsy of a tumor in 
the retromolar trigone using the CO2 laser (case 16).
Fig. 1. Clinical view of a pleomorphic adenoma located in the 
posterior third of the hard palate (case 10).
Fig. 2. Clinical view of surgical resection – biopsy of a palatal 
tumor using the cold scalpel (case 7).
third of the hard palate (33.2%)(Figure 1), followed by 
the soft palate (16.7%) and the upper lip mucosa (16.7%). 
Other locations were the cheek mucosa and the region 
of the retromolar trigone, with a frequency of 11.1% in 
both cases. Lastly, one case was documented in the lower 
lip mucosa (5.6%), and another in the tuberosity of the 
upper maxilla (5.6%). Of note are the facts that 49.9% 
of the MSGTs in our series were located in the palate, 
and that 94.1% of the palatal MSGTs were benign. The 
distribution of the 18 MSGTs by patient age and sex, 
histological diagnosis, location and duration of the lesion 
is shown in Table 1.
The most frequent clinical presentation of MSGT of our 
sample was in the form of a soft (9 cases) or slightly in-
durated lesion (9 cases) located in the hard or soft palate 
(49.9% of the total). Most of the tumors (72.2%) were 
asymptomatic, while 16.7% generated pain in response to 
palpation. Among the patients with symptoms (27.8%), 
swallowing discomfort was particularly common (80%).
In our review, only one MSGT presented perineural inva-
sion, without evidence of bone or vascular infiltration. At 
the time of clinical diagnosis, three cases presented super-
ficial ulceration (16.7%), while one showed telangiectasias 
of the adjacent oral mucosa (5.6%).
The mean tumor size was 1.0 x 1.3 cm, with two lesions 
reaching 2 cm in size. The mean time elapsed to the 
diagnosis of benign MSGT was 55 months. The single 
malignant lesion developed rapidly in 8 months before the 
histopathological diagnosis was established. The follow-up 
period ranged from 2-48 months (Table 2).
Complementary diagnostic tests were made in 44.6% 
of the cases, fundamentally in the form of CT (3 cases), 
followed by CT associated to preoperative biopsy (3 ca-
ses). In one case (12.5%) CT was requested and FNAB 
was performed, while in another case an MRI scan was 
requested (Table 2).
Surgical removal of the tumor with safety margins and 
posterior histopathological study was the treatment of 
first choice in 16 cases (88.9%). Two cases (11.1%) were 
subjected to an incisional biopsy, and in one them the his-
tological study confirmed the presence of malignancy.
As to the surgical techniques used for the treatment of 
MSGTs, 77.8% of the tumors in our sample were resected 
using the cold scalpel, while in the remaining four cases 
(22.2%) the CO2 laser was used at a power setting of 6W. 
Figures 2 and 3 show the different techniques used for 
resection-biopsy of the MSGTs in our series.
The postoperative controls revealed on case of local recu-
rrence (5.8%) among the overall benign lesions. The rest 
of MSGTs showed no evidence of recurrence over a mean 
follow-up period of 22 months (Table 2).
Discussion
Tumors originating in the minor salivary glands are 
infrequent, and represent less than 20% of all salivary 
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neoplasms. Racial and geographic variations in their fre-
quency and distribution have been reported (7-9). Most 
studies of salivary neoplasms include both the major and 
the minor salivary glands, and few articles focus only on 
MSGTs. In addition, there is great variability regarding 
the different diagnostic criteria applied to salivary glands 
tumors in the different classifications of the WHO (3). In 
our study, all cases were histologically re-evaluated based 
on the more recent salivary gland tumor classification 
of 2005. However, most of the studies reviewed in the 
literature are based on earlier classifications; as a result, 
comparisons must be established with caution (4). 
In our series the incidence of MSGTs was very low (0.9%) 
in relation to the total biopsies performed during the stu-
dy period (1997-2007). This is explained by the fact that 
the patients were received in our Service of Oral Surgery 
from the primary care setting, which usually refers tumor 
patients to hospital centers.
MSGTs can be located anywhere in the upper aerodiges-
tive tract, though the most frequently affected location 
Table 2. Distribution of minor salivary gland tumors according to clinical symptoms, the need for complementary tests, treatment and 
technique, follow-up and relapse.
CT: computed tomography; RSM: surgical resection with safety margins; MRI: magnetic resonance imaging; RT: radiotherapy; FNAB: 
fine needle aspiration biopsy.
             
Case Symptoms Complementary tests Treatment Technique
Follow-up 
(months)
Relapse
1 No No RSM CO2 laser 18 No
2 No CT RSM
Cold 
scalpel
48 No
3 No
CT and preoperative 
biopsy
RSM
Cold 
scalpel
36 No
4
Swallowing 
discomfort
CT and FNAB RSM
Cold 
scalpel
24 No
5 No No RSM
Cold 
scalpel
18 No
6
Swallowing 
discomfort, pain 
on palpation
No RSM
Cold 
scalpel
24 No
7 No No RSM
Cold 
scalpel
15 No
8 No No RSM
Cold 
scalpel
48 No
9 No No RSM CO2 laser 36 No
10 No No RSM
Cold 
scalpel
12 No
11 No CT RSM
Cold 
scalpel
24 No
12
Swallowing 
discomfort
No RSM
Cold 
scalpel
36 No
13
Swallowing 
discomfort, pain 
on palpation
CT and preoperative 
biopsy
Incisional biopsy. 
Partial maxillectomy 
and RT
Cold 
scalpel
24 No
14 No
CT and preoperative 
biopsy
RSM
Cold 
scalpel
10 No
15 Pain on palpation No
Incisional biopsy. 
RSM
Cold 
scalpel
12 No
16 No MRI RSM CO2 laser 8 No
17 No CT RSM
Cold 
scalpel and 
CO2 laser
3 1 month
18 No No RSM
Cold 
scalpel
2 No
Mean
22
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is the oral cavity, and particularly the palate – where the 
concentration of minor salivary glands is greater. Such 
lesions also can be found in the cheek mucosa, in the re-
gion of the retromolar trigone, the lips, the oropharynx, 
or in the nasal cavities and paranasal sinuses (5,8,10). In 
the series published by Waldron et al. (11), the palate was 
the most commonly affected location (42.5%), followed 
by the upper lip (18.5%), oral mucosa (15%), retromolar 
trigone (5.4%), floor of the mouth (4.9%) and lower lip 
(3.3%), among other zones. In contrast, other authors 
report a higher presence of MSGTs in the palatal region, 
representing 65-80% of the total (1-3,5,7). In our review, 
the preferential location of MSGTs was the posterior third 
of the hard palate (33.2%), followed by the soft palate 
(16.7%), the upper lip mucosa (16.7%), cheek mucosa 
(11.1%), and retromolar trigone (11.1%). A single case 
was located in the lower lip mucosa (5.6%), with another 
case in the tuberosity of the upper maxilla (5.6%). Thus, 
49.9% of the MSGTs were located in the palate, and 94.1% 
of the total palatal MSGTs were benign.
The proportion of malignant minor salivary gland tumors 
is close to 50%, though agreement is lacking as regards the 
incidence of malignancy in the different studies published 
in the literature to date (1,2,4,7-10,12-14). In contrapo-
sition to the most important MSGT series found in the 
literature, we recorded only one case of malignancy (5.6%). 
This again may be due to the fact that the patients were 
referred to our Service from the primary care setting, not 
from specific institutions such as cancer reference centers 
– where the incidence of salivary neoplasms is biased in 
favor of malignant lesions. Consequently, our findings are 
in line with those of earlier publications (2,7,11,12,14-17) 
showing a predominance of benign tumors versus malig-
nant lesions, with a percentage incidence of 51.3-72.1%. In 
contrast, other studies have reported a variable proportion 
of malignancy of between 62.8-88.2% (9,18-20). 
According to different authors, MSGTs can appear at any 
age, though most such lesions appear between the fifth and 
seventh decades of life (49.8% of our sample), and mainly 
affect women (7). Of our 18 MSGTs, 12 corresponded to 
women (66.7%) and 6 to men (33.3%) – in coincidence 
with other publications (7,8,11).
The most common benign histological type was pleomor-
phic adenoma (PA)(55.3%), in coincidence with different 
studies (1,2,5,7-11,13,15,21) that report a variable inciden-
ce of between 40-72% of all salivary gland tumors. The 
exception is the low incidence (19%) of PA lesions reported 
by Spiro (21). Likewise, PA has been reported to present a 
predilection for the hard palate and the posterior third of 
the soft palate, followed by the cheek and lip mucosas – in 
coincidence with our own results. Some authors consider 
pleomorphic adenomas to correspond to low-grade ma-
lignancies, based on the following characteristics: poorly 
defined limits, multifocal presentation, aggressivity, the 
capacity to relapse, and potential malignization over the 
long term (11). Pleomorphic adenoma relapse, which is 
almost always due to incomplete surgical resection of the 
lesion, manifests especially in the form of multiple foci, 
and is estimated to occur in 5-30% of cases.
Cystadenoma was the second most frequent benign tu-
mor in our series (11.1%), though the incidence reported 
in the literature is lower (between 2-4.7% of all salivary 
neoplasms)(11,22). In the most important series, 65% 
of  all cystadenomas are located in the major salivary 
glands, while 35% are found in the minor salivary glands 
(22-25). 
Warthin’s tumor is the second most common benign sa-
livary gland tumor after PA, representing 10-15% of all 
salivary gland tumors. Although it may be regarded as 
exclusively a parotid gland tumor, some cases have been 
reported in the submaxillary gland, and even in the minor 
salivary glands at lip and palatal level. This coincides with 
our only such documented lesion (5.6%), located in the 
posterior third of the hard palate.
Regarding malignant tumors of the minor salivary glands, 
only one such lesion was found in our study (5.6%), co-
rresponding to low-grade polymorphic adenocarcinoma 
(LGPA). This tumor is characterized by its cytological 
uniformity, morphological diversity and low metastasizing 
potential (1,2,11). In concordance with the case in our 
series, Kovalic et al. (26) advocate combined therapy in 
the form of surgical removal with safety margins, asso-
ciated to radiotherapy (RT), for carcinomas of the palatal 
minor salivary glands. However, some authors consider 
that RT may induce malignization of possible remnant 
tumor cells (27).
Salivary gland tumor growth is usually slow, with an esti-
mated evolutive course of between 3-6 years. This agrees 
with our own observed average of 4.6 years.
As regards the use of complementary studies, computed 
tomography (CT) was the most widely requested techni-
que (38,9%), either alone or in combination with other 
diagnostic procedures such as preoperative biopsies or 
fine needle aspiration biopsy (FNAB). A cytological study 
based on FNAB of salivary gland lesions reported histo-
pathological correlation in 40% of the benign neoplasms 
and in 80% of the malignant lesions (28), while Chan et 
al. (29) reported a diagnostic accuracy of 77%. In one case 
of our series, FNAB reported the presence of PA, which 
was posteriorly confirmed by histopathological study of 
the tumor (Table 2). Cerulli et al. (30), on comparing the 
diagnostic precision of FNAB cytology and preoperative 
biopsy with the histopathological study of the resection 
piece, found FNAB to offer an accuracy of 91.6%, while 
correlation of the preoperative biopsy to the final histo-
pathological report was 100%.
The treatment of choice for benign MSGTs is surgical 
removal with safety margins, followed by histopatholo-
gical study to establish the final diagnosis. In our series, 
postoperative follow-up identified one case of local relapse 
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one month after surgical resection. This case corresponded 
to Warthin’s tumor (5.8% of the total benign MSGTs), in 
coincidence with earlier publications describing a variable 
recurrence rate of 5-30%. Periodic controls are therefore 
advised in patients with MSGTs, due to the important 
relapse potential and aggressivity of these lesions.
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